Aaron Royston, M.D., M.B.A. is a Managing Partner at venBio with a background in life science investing, healthcare strategy, and as an entrepreneur. Dr. Royston led venBio’s investments into Akero Therapeutics (Nasdaq: AKRO), Harmony Biosciences (Nasdaq: HRMY), Apellis Pharmaceuticals (Nasdaq: APLS), and Menlo Therapeutics (Nasdaq: MNLO), and currently serves as a director on the boards of multiple private companies. Prior to joining venBio, Dr. Royston was a member of the investment team at Vivo Capital, a life science venture capital firm. Previously, he worked at Bain & Company, where he advised biotechnology companies on a range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. Dr. Royston received his B.S. in biological sciences from Duke University, and his M.D. and M.B.A. degrees from the University of Pennsylvania.